Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of “Hold” from Brokerages

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been given an average rating of “Hold” by the seven analysts that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $4.94.

A number of equities research analysts recently weighed in on the stock. BTIG Research lowered shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Robert W. Baird cut shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $10.00 to $1.00 in a research report on Thursday, December 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. Evercore ISI restated an “in-line” rating and set a $0.70 price objective (down previously from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. Finally, Baird R W downgraded shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th.

Carisma Therapeutics Price Performance

Shares of NASDAQ:CARM opened at $0.39 on Friday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. The stock’s 50 day moving average is $0.44 and its 200-day moving average is $0.68. Carisma Therapeutics has a twelve month low of $0.35 and a twelve month high of $2.39. The firm has a market capitalization of $16.08 million, a price-to-earnings ratio of -0.25 and a beta of 1.55.

Institutional Trading of Carisma Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CARM. Wexford Capital LP lifted its stake in Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares in the last quarter. Renaissance Technologies LLC grew its position in Carisma Therapeutics by 11.9% in the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock worth $97,000 after acquiring an additional 24,600 shares in the last quarter. Finally, Barclays PLC increased its stake in Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the last quarter. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.